Homepage
Author:
Spago Nanomedical
Posted Date:
May 19, 2026
Spago Nanomedical Publishes the Annual Report for 2025
Spago Nanomedical
May 19, 2026
Spago Nanomedical Presents Tumorad(R) Clinical Data at the International ANZSNM 2026 Conference
Spago Nanomedical
May 18, 2026
Notice To Annual General Meeting of Spago Nanomedical AB (PUBL)
Spago Nanomedical
May 11, 2026
Spago Nanomedical Interim Report January-March 2026
Spago Nanomedical
May 7, 2026
Spago Nanomedical’s Phase I/IIa study Tumorad-01 Meets a Primary Endpoint and Provides Further Visible Tumor Uptake
Spago Nanomedical
May 6, 2026
Spago Nanomedical Continues Recruitment in The Phase I/IIa Tumorad-01 Study Following Positive DMC Recommendation
Spago Nanomedical
March 17, 2026
Spago Nanomedical Strengthens CMC and Supply Capabilities to Support Next Phase of Tumorad Development
Spago Nanomedical
March 10, 2026
Spago Nanomedical Year-End Report January-December, 2025
Spago Nanomedical
February 7, 2026
